Academic High Content Analysis: Applications in Basic and Translational Research
Event details
| Date | 22.07.2013 |
| Hour | 12:15 › 13:15 |
| Speaker |
Justin D. Boyd, Ph.D., Laboratory for Drug Discovery in Neurodegeneration, Harvard Medical School, Boston, MA (USA) Bio: Dr. Justin D. Boyd is drug discovery scientist interested in developing high efficiency and high efficacy platforms for early and late stage drug discovery. Platforms include high performance computation for virtual screening and molecular dynamics; high content analysis for cell-based phenotypic screening; and surrogate cellular assays for biomarker analysis for in vivo drug efficacy. He is a Co-Founder of PathDrugomics Inc, Co-Founder and Chair of the Board of the Chattanooga Research Institute (CRI), and is a Leads Discovery Scientist in the Laboratory of Drug Discovery in Neurodegeneration, an affiliate lab of the Harvard NeuroDiscovery Center. Prior to his current positions, Dr. Boyd worked at the National Institutes of Health as a visiting Scientist for Evotec, a German pharmaceutical company, and as a Postdoctoral Fellow in the Laboratory of Molecular Biology at the National Institute for Neurological Disorders and Stroke. Dr. Boyd has a Ph.D. in Interdisciplinary Sciences with a specialty in Neuroscience from the University of Tennessee Health Science Center and a Bachelor of Science in Biology from Rhodes College. As CRI’s Co-Founder and Chair of the Board, Dr. Boyd is responsible for the launch of CRI’s platform developments through academic and business partnerships. At Harvard, Dr. Boyd directs the High Content Imaging and Analysis program and is developing ex vivo biomarker analytical assays to monitor drug efficacy. Dr. Boyd is also a technology consultant for the biotech and pharmaceutical industries across the country. Dr. Boyd has fifteen years experience in research in neuroscience, stem cell research and drug discovery. He is published in the fields of neurobiology, stem cell biology, infectious disease and drug discovery, reflecting his strong experience in interdisciplinary approaches to research. |
| Location | |
| Category | Conferences - Seminars |
BIOENGINEERING SANDWICH SEMINAR
The current drug discovery environment requires academic institutions to deliver more advanced programs into the pipeline. The Laboratory of Drug Discovery in Neurodegeneration, a Harvard NeuroDiscovery Center Lab , facilitates in accelerating academic drug discovery by providing resources to the basic researchers within the Harvard and greater Boston area that enable drug discovery activities from screening to lead optimization. The latest and fastest growing platform within LDDN is the High Content Platform, an automated imaging and image analysis platform. Image based assays provide a richer insight into the decision making process of compound screening. It also provides a means to mine data for multiple phenotypic fingerprints. Dr. Boyd will present an overview of the LDDN and how it deploys high content analysis in academic basic and translational research.
The current drug discovery environment requires academic institutions to deliver more advanced programs into the pipeline. The Laboratory of Drug Discovery in Neurodegeneration, a Harvard NeuroDiscovery Center Lab , facilitates in accelerating academic drug discovery by providing resources to the basic researchers within the Harvard and greater Boston area that enable drug discovery activities from screening to lead optimization. The latest and fastest growing platform within LDDN is the High Content Platform, an automated imaging and image analysis platform. Image based assays provide a richer insight into the decision making process of compound screening. It also provides a means to mine data for multiple phenotypic fingerprints. Dr. Boyd will present an overview of the LDDN and how it deploys high content analysis in academic basic and translational research.
Links
Practical information
- Informed public
- Free
- This event is internal
Organizer
- Dr. Bernard Schneider, Research Associate